CAN compared with TBPH: revenue, margins and what each company keeps, and the suppliers and customers both name

CANCanaan Inc.

Mkt capRevenueRevenue

TBPHTheravance Biopharma, Inc.

Mkt capRevenueRevenue

Compare

CANCanaan Inc.

TBPHTheravance Biopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CAN1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Sep 8 '26±36.4%▼−10.22%×0.28

TBPH

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▼−0.12%×0.02

May 7 '26±10.3%▲+0.47%×0.05

= impliedCAN realized, solidTBPH realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.0%

▲+1.30%

×0.11

Q3 FY25±24.6%▲+22.68%×0.92

CANCanaan Inc.

0.18▼−0.06%· post 0.19

Mkt cap$133.1MRevenue—Revenue—

TBPHTheravance Biopharma, Inc.

17.03▲+0.02%· post 17.04

ClosedNov 6 '26

Mkt cap$884.2MRevenue$21MQ2 FY26Revenue$107MFY25

Compare

ClosedNov 6 '26

CANCanaan Inc.

TBPHTheravance Biopharma, Inc.

0.18▼−0.06%post 0.19

Price

17.03▲+0.02%post 17.04

$133.1M

Mkt cap

$884.2M

—

Revenue

$21MQ2 FY26

—

Revenue

$107MFY25

CAN0.18▼−0.06%vsTBPH17.03▲+0.02%ClosedNov 6 '26